openPR Logo
Press release

Relapsing-Remitting Multiple Sclerosis (RRMS) Pipeline Analysis, 2022 | In-depth Insights Into the Clinical, Commercial and Regulatory Developments in the Therapeutic Domain

11-24-2022 12:56 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Relapsing-Remitting Multiple Sclerosis (RRMS) Pipeline

As per DelveInsight's assessment, globally, about 28+ key pharma and biotech companies are working on 28+ pipeline drugs in the Relapsing-Remitting Multiple Sclerosis therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types.

The "Relapsing-Remitting Multiple Sclerosis (RRMS) Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Relapsing-Remitting Multiple Sclerosis Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Relapsing-Remitting Multiple Sclerosis Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing therapies in the Relapsing-Remitting Multiple Sclerosis Market.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Relapsing-Remitting Multiple Sclerosis treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Relapsing-Remitting Multiple Sclerosis market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Delveinsight's Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Learn More About the Future Therapeutics Outlook:

Relapsing-Remitting Multiple Sclerosis Therapeutics Analysis
There are approx. 28+ key companies developing therapies for Relapsing-Remitting Multiple Sclerosis (RRMS). Currently, Immunic has its Relapsing-Remitting Multiple Sclerosis (RRMS) drug candidates in the most advanced stage of clinical development.

Some of the Key Companies in the Relapsing-Remitting Multiple Sclerosis Therapeutics Market Include:
• TG Therapeutics
• Novartis
• Sanofi
• Cinnagen
• Polpharma Biologics
• Immunic
• Mapi Pharma
• Biocad
• Apimeds
• Genentech (Roche)
• Merck
• Immune Response BioPharma
• Clene Nanomedicine
• InnoCare Pharma
• Oryzon Genomics
• GeNeuro SA
• AbbVie
• Emerald Health Pharmaceuticals
• GlaxoSmithKline
• RedHill Biopharma

Relapsing-Remitting Multiple Sclerosis (RRMS) Drugs Covered in the Report Include:
• IMU-838: Immunic
• Fenebrutinib: Roche
• Vafidemstat: Oryzon Genomics
• Temelimab: GeNeuro SA
• Elezanumab: AbbVie
And many others

Get an in-depth Assessment of the Emerging Therapies and Key Companies:

Table of Content
1. Report Introduction
2. Executive Summary
3. Relapsing-Remitting Multiple Sclerosis Current Treatment Patterns
4. Relapsing-Remitting Multiple Sclerosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Relapsing-Remitting Multiple Sclerosis Late-Stage Products (Phase-III)
7. Relapsing-Remitting Multiple Sclerosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Relapsing-Remitting Multiple Sclerosis Discontinued Products
13. Relapsing-Remitting Multiple Sclerosis Product Profiles
14. Relapsing-Remitting Multiple Sclerosis Key Companies
15. Relapsing-Remitting Multiple Sclerosis Key Products
16. Dormant and Discontinued Products
17. Relapsing-Remitting Multiple Sclerosis Unmet Needs
18. Relapsing-Remitting Multiple Sclerosis Future Perspectives
19. Relapsing-Remitting Multiple Sclerosis Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.

Request the Sample PDF to Get Detailed Insights About the Reports Offerings:

Shruti Thakur
Manager - Marketing & International Branding

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Relapsing-Remitting Multiple Sclerosis (RRMS) Pipeline Analysis, 2022 | In-depth Insights Into the Clinical, Commercial and Regulatory Developments in the Therapeutic Domain here

News-ID: 2820291 • Views: 171

More Releases from DelveInsight Business Research

Acute ischemic stroke Market is expected to grow at a decent CAGR during forecas …
Acute Ischemic stroke results from a sudden cessation of adequate amounts of blood reaching parts of the brain. Ischemic strokes can be divided according to territory affected or mechanism. Clots are either thrombotic or embolic, depending on where they develop within the body. A thrombotic stroke, the more common of the two, occurs when a clot forms within an artery in the brain. An embolic stroke occurs when a clot
Acute Intermittent Porphyria Market is expected to grow at a decent CAGR, estima …
Acute Intermittent Porphyria is a genetic metabolic disorder. It affects the production of heme, the oxygen-binding prosthetic group of hemoglobin. Generally, it is characterized by a deficiency of the enzyme porphobilinogen deaminase. DelveInsight's "Acute Intermittent Porphyria Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Acute Intermittent Porphyria, historical and forecasted epidemiology as well as the Acute Intermittent Porphyria market trends in the United States, EU5 (Germany,
Pulmonary Arterial Hypertension Pipeline Insight Research Report | 55+ Companies …
DelveInsight's, "Pulmonary Arterial Hypertension Pipeline Insight, 2022," report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in the Pulmonary Arterial Hypertension pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Around 55+ key companies are developing therapies
Complicated Urinary Tract Infections Market to Witness Growth at a CAGR of 5.9%
The dynamics of the complicated urinary tract infection market are anticipated to change in the coming years owing to the improvement in the rise in the number of healthcare spending across the world and rising cases of complicated urinary tract infection. Leading companies like Allecra Therapeutics, Venatorx Pharmaceuticals, Wockhardt, and others are developing drugs for complicated urinary tract infection treatment. The Complicated Urinary Tract Infection market report provides current treatment practices,

All 5 Releases

More Releases for Multiple

Massive MIMO (Multiple-input multiple-output) Market 2022-2028 | Detailed Report
The market report delivers an all-inclusive analysis of the market structure along with a forecast of the various segments and sub-segments of the Massive MIMO (Multiple-input multiple-output) industry. This wide-ranging market research report acts as a backbone for the success of business in any niche. The Massive MIMO (Multiple-input multiple-output) market survey report has been prepared by conducting market research in a systematic manner. Moreover, the Massive MIMO (Multiple-input multiple-output)
Multiple Sclerosis Therapeutics Market – Increasing prevalence of multiple scl …
Multiple Sclerosis Therapeutics Market report is a exploration database spread across colorful runners with multiple tables and numbers in it. The exploration covers a precious source of perceptive information for business strategists. Multiple Sclerosis Therapeutics Industry provides the overview with growth analysis and literal & futuristic cost, profit, demand and force data (as applicable). The exploration judges give an elegant description of the value chain and its distributor analysis. This comprehensive
Global Multiple Sclerosis Market Size, Global Multiple Sclerosis Market Share, G …
The Global Multiple Sclerosis Market Size is majorly driven by the factors such as rising number of consolidations between the market players for exploring the untapped market opportunity across the world. Request for Sample of This Research Report @ Top Key Player:- Hoffmann-La Roche Ltd. Bayer Healthcare AG Teva Pharmaceuticals GlaxoSmithKline AbbVie Inc. Sonafi Pasteur Pfizer Inc. Merck & Company Novartis AG AB Science Opexa Multiple Sclerosis (MS) is a disease in which the insulating covers of nerves and spinal cord are
Multiple Ion Beam Microscopes Market- Multiple Ion Beam Microscopes Have Huge Ap …
An ion beam is a kind of charged particle beam which consists of ions. With the advancement of nanotechnology new and advanced fabrication techniques are required which helps in production of functional features in much smaller scales. Advanced techniques are being used for applications in material science which uses image surfaces producing different features in a nanoscale. Gas field ion source technology has the capability of combining helium and neon
Smart Antenna Market Report 2018: Segmentation by Type (Switched Beam Smart Ante …
Global Smart Antenna market research report provides company profile for Cobham Antenna Systems(Suffolk, United Kingdom), Intel Corp.( Santa Clara, California, United States), Samsung Electronics CoLtd. ( Seoul, South Korea), ArrayComm LLC ( California, United States), Alcatel-Lucent International Holdings Inc.( Paris, France), Motorola Solutions Inc.( Illinois, the U.S.) and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017,
Thermoseal Group Multiple Award Winners
For the second year in a row, Thermoseal Group is the winner of the coveted Glass and Glazing Industry’s G-Award for ‘Component Supplier of the Year’ as announced at the prestigious Gala Dinner held at the Hilton on Park Lane Hotel in London on Friday 18 November 2016. This was a great day for Thermoseal Group who were also announced winners at two other awards events held that day